{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:27:32Z","timestamp":1763036852516},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/icl.0000000000000055","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T11:02:48Z","timestamp":1406804568000},"page":"283-288","source":"Crossref","is-referenced-by-count":14,"title":["Topical Cyclosporine A 1% for the Treatment of Chronic Ocular Surface Inflammation"],"prefix":"10.1097","volume":"40","author":[{"given":"Ashwinee","family":"Ragam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton M.","family":"Kolomeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha V.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliott","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/oxfordjournals.epirev.a036304","article-title":"Epidemiology of epidemic keratoconjunctivitis.","volume":"9","author":"Ford","year":"1987","journal-title":"Epidemiol Rev"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical review: Topical ophthalmic use of cyclosporin A.","volume":"18","author":"Utine","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R3-3-20210128","first-page":"475","article-title":". Epidemic keratoconjunctivitis: The current situation and recommendations for prevention and treatment.","volume":"108","author":"Meyer-Rusenberg","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF01569415","article-title":". Physiologic and genetic factors for process development of cyclosporine fermentations.","volume":"1","author":"Agathos","year":"1986","journal-title":"J Ind Microbiol"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanism of action of cyclosporine.","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004397-199303340-00005","article-title":"Clinical use of cyclosporine in ocular disease.","volume":"33","author":"de Smet","year":"1993","journal-title":"Int Ophthalmol Clin"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0167-5699(93)90048-P","article-title":"FK506 and cyclosporin, molecular probes for studying intracellular signal transduction.","volume":"14","author":"Liu","year":"1993","journal-title":"Immunol Today"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S1542-0124(12)70238-0","article-title":". Pathways of corneal and ocular surface inflammation: A perspective from the cullen symposium.","volume":"3","author":"McDermott","year":"2005","journal-title":"Ocul Surf"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0039-6257(86)90035-4","article-title":"Cyclosporine: Immunology, pharmacology and therapeutic uses.","volume":"31","author":"Nussenblatt","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":". Cyclosporine for ocular inflammatory disease.","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14740338.7.1.79","article-title":"Uses and safety profile of ciclosporin in ophthalmology.","volume":"7","author":"Kashani","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bjo.2005.070888","article-title":"Topical ciclosporin in the treatment of ocular surface disorders.","volume":"89","author":"Tatlipinar","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/ICO.0b013e318033bd25","article-title":"Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: A long-term follow-up.","volume":"27","author":"Sahin","year":"2008","journal-title":"Cornea"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/ICO.0b013e31812dfab3","article-title":"Management of severe allergic conjunctivitis with topical cyclosporin a 0.05 eyedrops.","volume":"26","author":"Ozcan","year":"2007","journal-title":"Cornea"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2147\/OPTH.S30261","article-title":". PERSIST: Physicians evaluation of Restasis satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05 for dry eye: A retrospective review.","volume":"6","author":"Mah","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2415-12-42","article-title":". Cyclosporine a 0.05 eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.","volume":"12","author":"Okumus","year":"2012","journal-title":"BMC Ophthalmol"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/ICO.0b013e31828ffdf8","article-title":"Tear cytokine levels in vernal keratoconjunctivitis: The effect of topical 0.05 cyclosporine A therapy.","volume":"32","author":"Oray","year":"2013","journal-title":"Cornea"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0181-5512(07)91357-1","article-title":". Efficacy of topical 2 cyclosporine A as a steroid-sparing agent in steroid-dependent vernal keratoconjunctivitis article in French.","volume":"30","author":"Doan","year":"2007","journal-title":"J Fr Ophtalmol"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":". A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis.","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/ICO.0b013e3181c33034","article-title":". Topical treatment with 1 cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.","volume":"29","author":"Levinger","year":"2010","journal-title":"Cornea"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/ICO.0b013e31820cd607","article-title":"Cyclosporine A 1 eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis.","volume":"30","author":"Jeng","year":"2011","journal-title":"Cornea"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/039463201002300322","article-title":". Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis.","volume":"23","author":"Pucci","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00003226-199307000-00007","article-title":". Pilot trial of cyclosporin 1 ophthalmic ointment in the treatment of keratoconjunctivitis sicca.","volume":"12","author":"Laibovitz","year":"1993","journal-title":"Cornea"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ophtha.2010.08.027","article-title":". A standardized grading system for scleritis.","volume":"118","author":"Sen","year":"2011","journal-title":"Ophthalmology"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/bjo.2005.082461","article-title":". Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis.","volume":"90","author":"Daniell","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bjo.73.8.600","article-title":"Penetration of 2 cyclosporin eyedrops into human aqueous humour.","volume":"73","author":"Diaz-Llopis","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1076\/ceyr.18.2.91.5381","article-title":". Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.","volume":"18","author":"Acheampong","year":"1999","journal-title":"Curr Eye Res"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":". Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease.","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"}],"container-title":["Eye & Contact Lens: Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICL.0000000000000055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:59:37Z","timestamp":1620953977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00140068-201409000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/icl.0000000000000055","relation":{},"ISSN":["1542-2321"],"issn-type":[{"value":"1542-2321","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}